SUO 2018 AUA/Spring Meeting
Saturday, May 19, 2018

Hilton San Francisco Union Square
San Francisco, California

SUO/SBUR Morning Joint Session
8:00 a.m. - 11:45 a.m.

SUO Afternoon Session
12:30 p.m. - 5:05 p.m.
FRIDAY, MAY 18, 2018

SUO Board of Directors Dinner & Board Meeting
Hilton San Francisco Union Square
Plaza B, Lobby Level
6:00 p.m. – 10:00 p.m.

SUO-CTC Board of Directors Meeting
(for CTC Board and CTC Committees only)
Marriott Marquis
Yerba Buena Salon 10-12, Lower B2 Level
11:30 a.m. – 1:00 p.m.

SATURDAY, MAY 19, 2018

SUO/SBUR Joint Meeting (Morning Program)
Hilton San Francisco Union Square
Grand Ballroom B
8:00 a.m. – 11:45 a.m.

Donald S. Coffey Lecture Speaker: Lieping Chen, MD, PhD

Dr. Chen’s study established the foundation for the anti-PD-1/PD-L1 therapy for human cancer with contributions in both basic and translational research. In basic research, his laboratory co-discovered the PD-1/PD-L1 pathway and elucidated its functions. These findings include discovery of B7-H1 (PD-L1) molecule; its immune suppressive function as well as normal physiologic functions. In transalational research, his studies have singularly established the PD-1/PD-L1 pathway as target for cancer immunotherapy. These studies made the first link of the PD-L1/PD-1 pathway to cancer.

SUO/Y.U.O. RECEPTION
Hilton San Francisco Union Square
Grand Ballroom A
5:05 p.m. – 7:00 p.m.
Business Attire

Immediately following the afternoon session on Saturday, May 19, there will be a networking and socializing reception co-sponsored by the SUO and Young Urologic Oncologists (Y.U.O.). The reception will be held right next door to the general session room in Grand Ballroom A. Doors open at 5:05 p.m. Seasoned urologic oncologists, as well as residents, fellows and medical students are welcome to attend.

SUO AUA/Spring Meeting (Afternoon Program)
Hilton San Francisco Union Square
Grand Ballroom B
12:30 p.m. – 5:05 p.m.

Whitmore Lecture Speaker: W. Marston Linehan, MD

Dr. Linehan has had a long standing interest in identification of the genetic basis of cancer of the kidney. By studying patients and families with kidney cancer, he and his colleagues identified the VHL gene for von Hippel-Lindau syndrome and showed that the VHL gene is also the gene for clear cell renal cell carcinoma. He and his colleagues identified the gene for Hereditary Papillary Renal Carcinoma (MET oncogene, type I papillary renal carcinoma) the FLCN gene (Birt Hogg Dubé syndrome, chromophobe renal carcinoma), the gene for TFE3 kidney cancer and described the germline fumarate hydratase and succinate dehydrogenase B/C/D mutations in the North American families with hereditary leiomyomatosis renal cell carcinoma (HLRCC) and SDH-RCC and described five new diseases.

SUO/Y.U.O. RECEPTION
Hilton San Francisco Union Square
Grand Ballroom A
5:05 p.m. – 7:00 p.m.
Business Attire

Immediately following the afternoon session on Saturday, May 19, there will be a networking and socializing reception co-sponsored by the SUO and Young Urologic Oncologists (Y.U.O.). The reception will be held right next door to the general session room in Grand Ballroom A. Doors open at 5:05 p.m. Seasoned urologic oncologists, as well as residents, fellows and medical students are welcome to attend.

2018 SUO AWARD WINNERS

Whitmore Lecturer: W. Marston Linehan, MD

The Willet F. Whitmore Jr. Lectureship was established in 1993 as a keynote address to be delivered at the Annual Meeting and as a tribute to Dr. Whitmore, who embodied the field of urologic oncology as a premier urologic surgeon and as a pioneer in the multidisciplinary aspects of urologic care.

SUO Medal: Robert Uzzo, MD

Awarded to an individual for a specific achievement and/or significant contributions in the field of urologic oncology.

Young Investigator Award: Todd Morgan, MD

Recognition by the Society of excellence for a singular contribution or consistent pattern of performance in clinical practice and/or basic research that has contributed to improvement of clinical care and progress in science. Awarded to a urologist who is within 10 years of completion of residency or fellowship.

Distinguished Service Award: Leonard G. Gomella, MD, FACS

Awarded to a urologist whose actions at work or in the community exceed job expectations and reflect values of compassion, respect, trust, commitment to excellence and teamwork, and also educate the community about prostate cancer.
Educational Needs
Pathophysiology of the GU tract is complex. Sub-specialization has helped us develop deeper understanding, but has limited broader dissemination among various sub-specialists. There is urgent need for cross training and inter-disciplinary education among various sub-specialists treating or studying GU diseases in order to highlight common drivers of the disease process along the GU tract.

Educational Objectives
At the conclusion of the SUO/SBUR Morning Session at the AUA 2018 Annual Meeting, attendees will be able to:

- Explain how immunotherapy can improve current therapies and overcome therapeutic resistance.
- Identify the challenges associated with clinical developments in immunomodulation and immunotherapy in GU cancer.
- Integrate the power of laboratory findings in immunomodulation to translate to clinical applications for advanced GU cancer.
- Describe the challenges of translating immunomodulation and immunotherapy into clinical decision making on institutional, corporate, or population bases.
- Recognize a future that incorporates immunotherapy with current therapies in the field of urologic oncology.

SUO AFTERNOON SESSION EDUCATIONAL NEEDS AND OBJECTIVES

Educational Needs
The best methods for risk stratification prior choosing active surveillance for prostate cancer and how we can expand access to men outside of traditionally low risk criteria represents an unmet educational need. Contemporary urologists need up-to-date knowledge to optimally treat these men. In the absence of high quality randomized data, treatment of men with localized high-risk disease must be individualized and these strategies represent an unmet educational need. This also includes treatment of the primary tumor for men with metastatic prostate cancer.

Treatment strategies for patients with high-risk bladder cancer are complex. Understanding how best to manage patients who fail or are not eligible for standard of care approaches represents a great unmet need. There are multiple knowledge gaps with these approaches as well as how to integrate newer technologies into risk stratification and treatment selection.

In selecting the most appropriate therapeutic strategy for patients with RCC the audience should be able to evaluate the debates based on many controversies that exist in the field of RCC. The debates surrounding the most common arguments in management of RCC patients will help in evaluation of existing literature. Additional focus on molecular profiling may help bridge the knowledge gaps.

Educational Objectives
At the conclusion of the SUO Afternoon Session at the AUA 2018 Annual Meeting, attendees will be able to:

1. Describe the role of multiparametric MRI and novel biomarkers for selecting men for active surveillance of prostate cancer.
2. Discuss the role of active surveillance for men with intermediate risk prostate cancer.
3. Identify treatment options for men presenting with localized high risk prostate cancer including radical prostatectomy and radiation therapy.
4. Explain the potential role for local prostate directed therapy in men presenting with de novo metastatic prostate cancer.
5. Describe the current treatment guidelines for intravesical therapy in patients with non-muscle invasive bladder cancer.
6. Discuss the role for secondary intravesical agents or radical cystectomy in patients with BCG recurrent, refractory, or ineligible non-muscle invasive bladder cancer.
7. Identify treatment options for patients with invasive bladder cancer who are not eligible for platinum based neo-adjuvant chemotherapy.
8. Explain how additional testing such as molecular sub-typing and IHC can be utilized to guide treatment selection for patients with bladder cancer.
9. Identify patients with larger renal masses who may be best suited for active surveillance.
10. Learn about two types of surgical resections and their long-term functional and oncologic outcomes.
11. Explain the major drawbacks with adjuvant RCC trials and identify patients that may benefit the most from the adjuvant therapies.
12. Discuss the magnitude of molecular profiling and its use in RCC management.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The American Urological Association complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.
The morning session is a combined meeting of the Society of Urologic Oncology (SUO) and the Society of Basic Urologic Research (SBUR).

### SUO/SBUR: Immunotherapy in Genitourinary Cancer

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
</table>
| 8:00 a.m. - 8:05 a.m. | Welcome and Introduction                                            | SUO President: Christopher P. Evans, MD, FACS  
                     |                                                                   | SBUR President-Elect: Allen Gao, MD, PhD |
| 8:05 a.m. - 8:35 a.m. | Overview of Immunotherapy in GU                                      | James Gulley, MD, PhD, FACP           |
| 8:35 a.m. - 8:55 a.m. | Targeting Myeloid Derived Suppressor Cells in Urologic Cancers       | Timothy L. Ratliff, PhD              |
| 8:55 a.m. - 9:15 a.m. | Engaging the Immune System to Combat Prostate Cancer                 | Lauren C. Harshman, MD               |
| 9:15 a.m. - 9:30 a.m. | Panel Discussion and Questions                                       |                                      |
| 9:15 a.m. - 9:20 a.m. | Immunotherapy in Urothelial Cancer                                   | Siamak Daneshmand, MD, PhD           |
| 9:25 a.m. - 9:30 a.m. | Overview of Immunotherapy in Bladder Cancer                         | Timothy L. Ratliff, PhD              |
| 9:35 a.m. - 9:55 a.m. | Translational Research to Potentiate Immunotherapy in Urothelial Cancer | Chong-Xiang Pan, MD, PhD             |
| 9:55 a.m. - 10:15 a.m. | Immunotherapy in Renal Cell Carcinoma: Current Standing and Future Directions | Matthew T. Campbell, MD              |
| 10:15 a.m. - 10:35 a.m. | Refining Immunotherapy Combinations and Sequencing in Bladder Cancer | Joaquim Bellmunt, MD, PhD           |
| 10:35 a.m. - 10:50 a.m. | Panel Discussion and Questions                                       |                                      |
| 10:50 a.m. - 10:55 a.m. | Donald Coffey Lecture Introduction                                   |                                      |
| 10:55 a.m. - 11:35 a.m. | Donald Coffey Lecture                                                | Lieping Chen, MD, PhD                |
| 11:35 a.m. - 11:45 a.m. | Questions                                                           |                                      |

### SUO: Controversies in Urology

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
</table>
| 12:30 p.m. - 12:35 p.m. | Welcome and Introduction                                            | Program Chairs: Gennady Bratslavsky, MD  
                     |                                                                   | Marc A. Dall’Era, MD |
| 12:35 p.m. - 12:40 p.m. | Introduction to the Whitmore Lecture                               | President: Christopher P. Evans, MD, FACS  |
| 12:40 p.m. - 1:00 p.m. | Whitmore Lecture: The Genetic Basis of Kidney Cancer: Precision Surgical Management and Targeted Therapy | W. Marston Linehan, MD                |
| 1:00 p.m. - 1:10 p.m. | SUO Awards                                                          | President: Christopher P. Evans, MD, FACS  |
| 1:10 p.m. - 2:10 p.m. | Prostate Cancer                                                     | Moderator: Maxwell V. Meng, MD         |
| 1:22 p.m. - 1:28 p.m. | Risk Stratification for Active Surveillance                         | Speaker: Mohummad M. Siddiqui, MD      |
| 1:28 p.m. - 1:34 p.m. | Should We Offer Active Surveillance for Gleason 7 (3+4) Risk Disease? | Speaker: Andrew J. Stephenson, MD       |
| 1:34 p.m. - 1:46 p.m. | Treatment of High Risk Localized                                    | Speaker: Scott E. Eggener, MD          |
| 1:46 p.m. - 1:58 p.m. | Treatment of High Risk Advanced and M1 Disease: Is There a Role for Treatment of the Primary? | Speaker: Alberto Bossi, MD            |
| 1:58 p.m. - 2:08 p.m. | Panel Discussion/Q&A                                                |                                      |
2:08 p.m. - 2:14 p.m.  SUO-CTC Prostate Committee: SUO Trials Update and Other Important Trials  
Speaker: Daniel W. Lin, MD

2:14 p.m. - 2:20 p.m.  Three Articles Last Year that Changed or Influenced My Practice  
Speaker: Samir S. Taneja, MD

2:20 p.m. - 2:40 p.m.  Invited Guest Lecture: Selection of Appropriate Genitourinary Cancers for Immunotherapy  
Speaker: Jeffrey S. Ross, MD

2:40 p.m. - 2:55 p.m.  Break

2:55 p.m. - 4:05 p.m.  Bladder Cancer  
Moderator: Siamak Daneshmand, MD

2:55 p.m. - 3:01 p.m.  Adherence to Bladder Cancer Guidelines and Issues with Implementation  
Speaker: Ralph W. deVere White, MD

3:01 p.m. - 3:15 p.m.  High Risk BCG Recurrent/Refractory Disease

3:01 p.m. - 3:08 p.m.  Secondary Intravesical Therapy  
Speaker: Sima P. Porten, MD, MPH

3:08 p.m. - 3:15 p.m.  Immediate Cystectomy  
Speaker: Joseph Jacob, MD

3:15 p.m. - 3:29 p.m.  Treatment for MiBC for Cis-Platinum Ineligible Patients

3:15 p.m. - 3:22 p.m.  Immediate Cystectomy  
Speaker: Jonathan L. Wright, MD

3:22 p.m. - 3:29 p.m.  Other Systemic Options and Trials  
Speaker: Evan Y. Yu, MD

3:29 p.m. - 3:43 p.m.  Molecular Subtyping, Immunohistochemistry Influences My Treatment Selection

3:29 p.m. - 3:36 p.m.  Pro  
Speaker: Peter C. Black, MD

3:36 p.m. - 3:43 p.m.  Con  
Speaker: David J. McConkey, PhD

3:43 p.m. - 3:53 p.m.  Panel Discussion/Q&A

3:53 p.m. - 3:59 p.m.  SUO-CTC Bladder Committee: SUO Trials Update and Other Important Trials  
Speaker: Ashish M. Kamat, MD, MBBS

3:59 p.m. - 4:05 p.m.  Three Articles Last Year that Changed or Influenced My Practice  
Speaker: Badrinath R. Konety, MD, MBA

4:05 p.m. - 4:15 p.m.  Kidney Cancer  
Moderator: Viraj A. Master, MD, PhD, FACS

4:05 p.m. - 4:15 p.m.  Active Surveillance for Large Renal Masses is Appropriate

4:05 p.m. - 4:10 p.m.  Pro  
Speaker: Marc C. Smaldone, MD, MSHP

4:10 p.m. - 4:15 p.m.  Con  
Speaker: R. Houston Thompson, MD

4:15 p.m. - 4:25 p.m.  Tumor Enucleation for Sporadic T1 RCC is Oncologically Sound

4:15 p.m. - 4:20 p.m.  Pro  
Speaker: Ronald S. Boris, MD

4:20 p.m. - 4:25 p.m.  Con  
Speaker: E. Jason Abel, MD, FACS

4:25 p.m. - 4:35 p.m.  Adjuvant Therapy for High Risk RCC Should Be Used

4:25 p.m. - 4:30 p.m.  Pro  
Speaker: Daniel George, MD

4:35 p.m. - 4:45 p.m.  Ten Years of Big Data Changed the Way We Manage RCC

4:35 p.m. - 4:40 p.m.  Pro  
Speaker: Brian M. Shuch, MD

4:40 p.m. - 4:45 p.m.  Con  
Speaker: Jose A. Karam, MD

4:45 p.m. - 4:53 p.m.  Panel Discussion/Q&A

4:53 p.m. - 4:59 p.m.  SUO-CTC Renal Cell Carcinoma Committee: SUO Trials Update and Other Important Trials  
Speaker: Eric A. Singer, MD, MA, FACS

4:59 p.m. - 5:05 p.m.  Three Articles Last Year that Changed or Influenced My Practice  
Speaker: Ithaar Derweesh, MD

5:05 p.m.  Adjourn
2018 Educational Series:
Advanced and Castration-Resistant Prostate Cancer
Presented by the AUA in partnership with the SUO

EVIDENCE-BASED CLINICAL MANAGEMENT OF ADVANCED AND CAstration-RESISTANT PROSTATE CANCER - LIVE FORUMS

Sheraton Grand Phoenix, Phoenix, AZ | November 27, 2018

Designed for residents, fellows and advanced practice providers.

Attend this FREE, live, interactive forum for participants to engage with subject matter experts and mentors that will cover practice gaps for managing advanced and castration-resistant prostate cancer.

REGISTER NOW AT WWW.AUANET.ORG/CRPC2018

Stay tuned! The 2018 Educational Series is comprised of a variety of activities, including two live forums, four live webinars, webcasts and podcasts. Learn more at www.AUAnet.org/CRPC2018.

This educational series is supported by independent educational grants from Astellas, Ferring Pharmaceuticals Inc., Genomic Health, Medivation, Inc. a Pfizer company, Sanofi Genzyme, and Tolmar Pharmaceuticals, Inc.

Accreditation
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American Urological Association designates this live activity and enduring material for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
19TH ANNUAL MEETING OF THE SOCIETY OF UROLOGIC ONCOLOGY

Wednesday, November 28 – Friday, November 30, 2018
Abstract Submissions are now open!

Sheraton Grand Phoenix
340 North 3rd Street | Phoenix, Arizona | Phone: 1-800-325-3535

SUO is happy to provide a discounted room rate of $209, plus applicable tax at the conference hotel. The block may sell out prior to the hotel deadline, which is October 31, 2018. Attendees are strongly encouraged to make their reservations early.

Please visit our website at www.suonet.org for updates on the program, registration and CME information.

Thank You to our 2018 Industry Partners

Astellas and Pfizer Oncology
AstraZeneca
Genentech
Genomic Health
Janssen

YOU‘RE INVITED!

Y.U.O. Dinner
Date: Wednesday, November 28, 2018
Location: Camelback
Time: 6:30 p.m. - 9:00 p.m.

SUO Reception
Date: Thursday, November 29, 2018
Location: Encanto Ballroom
Time: 5:30 p.m. - 6:30 p.m.